MIST
No price yet
Announcements
Nothing here yet
Daily updates
FDA designations
Nothing here yet
News
- Milestone Pharmaceuticals enrolls the first European participant in the Phase 3 ReVeRA-301 clinical trialOct 9, 2026
- Milestone Pharmaceuticals enrolls the first Canadian participant in the pivotal Phase 3 ReVeRA-301 trial of etripamil nasal spray for AFib-RVRSep 24, 2026
- Milestone Pharmaceuticals received NMPA approval for etripamil nasal spray in PSVT in China, marking its first regulatory approval outside the U.S.Sep 7, 2026
- Milestone Pharmaceuticals initiated a pivotal Phase 3 trial of etripamil nasal spray for self-administered treatment of AFib with rapid ventricular rateAug 21, 2026
- Milestone announced CARDAMYST nasal spray became available on Express Scripts formulariesMar 31, 2026